Aura Biosciences Ownership

AURA Stock  USD 7.49  0.12  1.63%   
Aura Biosciences holds a total of 49.95 Million outstanding shares. The majority of Aura Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aura Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aura Biosciences. Please pay attention to any change in the institutional holdings of Aura Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Institutions82.85%Public14.06%Insiders100%
Some institutional investors establish a significant position in stocks such as Aura Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Aura Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.

Aura Stock Ownership Analysis

About 83.0% of the company shares are held by institutions such as insurance companies. The book value of Aura Biosciences was presently reported as 3.51. The company recorded a loss per share of 1.73. Aura Biosciences had not issued any dividends in recent years. Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts. Aura Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people. For more info on Aura Biosciences please contact Elisabet Pinos at 617 500 8864 or go to https://www.aurabiosciences.com.

Aura Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aura Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aura Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aura Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
De Los Pinos Elisabet over a week ago
Disposition of 20221 shares by De Los Pinos Elisabet of Aura Biosciences at 7.7541 subject to Rule 16b-3
 
Amy Elazzouzi over three weeks ago
Acquisition by Amy Elazzouzi of 29760 shares of Aura Biosciences at 7.68 subject to Rule 16b-3
 
Mattessich Antony C. over a month ago
Acquisition by Mattessich Antony C. of 10500 shares of Aura Biosciences subject to Rule 16b-3
 
Amy Elazzouzi over a month ago
Disposition of 1001 shares by Amy Elazzouzi of Aura Biosciences at 7.6715 subject to Rule 16b-3
 
Srivastava Sapna over three months ago
Acquisition by Srivastava Sapna of 16000 shares of Aura Biosciences at 12.83 subject to Rule 16b-3
 
Hopkins Janet Jill over three months ago
Disposition of 11822 shares by Hopkins Janet Jill of Aura Biosciences at 9.3608 subject to Rule 16b-3
 
Amy Elazzouzi over three months ago
Disposition of 553 shares by Amy Elazzouzi of Aura Biosciences at 10.7385 subject to Rule 16b-3
 
Amy Elazzouzi over three months ago
Insider Trading
 
Johnson David Michael over six months ago
Acquisition by Johnson David Michael of 14500 shares of Aura Biosciences at 6.93 subject to Rule 16b-3
 
Julie Feder over six months ago
Disposition of 89657 shares by Julie Feder of Aura Biosciences at 2.74 subject to Rule 16b-3
 
Kilroy Conor over six months ago
Acquisition by Kilroy Conor of 144000 shares of Aura Biosciences at 7.4 subject to Rule 16b-3
 
Kilroy Conor over six months ago
Acquisition by Kilroy Conor of 96000 shares of Aura Biosciences subject to Rule 16b-3

Aura Biosciences Outstanding Bonds

Aura Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aura Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aura bonds can be classified according to their maturity, which is the date when Aura Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…